2723b191-7c84-4edd-b0d0-da8ba4a1a894
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.400
- MYC_TARGETS_V2+0.400
- NOTCH_SIGNALING+0.400
- UNFOLDED_PROTEIN_RESPONSE+0.400
- ANGIOGENESIS+0.300
- E2F_TARGETS+0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- G2M_CHECKPOINT+0.300
- TGF_BETA_SIGNALING+0.300
- UV_RESPONSE_DN+0.300
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.300
- KRAS_SIGNALING_DN-0.300
- ESTROGEN_RESPONSE_LATE-0.200
- INTERFERON_GAMMA_RESPONSE-0.200
- BILE_ACID_METABOLISM-0.100
- COAGULATION-0.100
- ESTROGEN_RESPONSE_EARLY-0.100
- MYOGENESIS-0.100
- PANCREAS_BETA_CELLS-0.100
- WNT_BETA_CATENIN_SIGNALING-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934935 | — | — | 0.824 |
| 2 | 47c0b7df-a564-4e71-8d90-ba07bac40f59 | — | — | 0.821 |
| 3 | 67719D37-8CC2-42B5-AF44-6D5AC258FDB1 | — | — | 0.816 |
| 4 | 8ACC0F29-A39E-4C1C-A04C-ED6E5FA80C24 | — | — | 0.812 |
| 5 | MNG308 | — | — | 0.801 |
| 6 | A3153235-3128-40AC-9371-AFA1F61E3E59 | — | — | 0.795 |
| 7 | BDEB76B7-B7E0-4058-82A2-77E93748C936 | — | — | 0.791 |
| 8 | SAMN03290906 | — | — | 0.790 |
| 9 | SRR934939 | — | — | 0.787 |
| 10 | SRR934967 | — | — | 0.786 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.400 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.400 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.200 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |